Edition:
India

Michael Erman

Novartis says it knew of Zolgensma data problems before U.S. approval

07 Aug 2019

NEW YORK Swiss Drugmaker Novartis AG on Wednesday said it knew about discrepancies in data it submitted to regulators as it sought approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed an internal investigation.

Novartis says knew about Zolgensma data problems before U.S. approval

07 Aug 2019

NEW YORK, Aug 7 Drugmaker Novartis on Wednesday acknowledged that there were discrepancies with data it had submitted to regulators for approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed its internal investigation.

U.S. FDA says some data testing Novartis' $2 million gene therapy was manipulated

07 Aug 2019

NEW YORK The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis' more than $2 million gene therapy Zolgensma was manipulated, but the agency believes the treatment should remain on the market.

Trump firms up plan to import medicines; pharma companies resist

01 Aug 2019

The Trump administration took a step Wednesday toward allowing importation of medicines from Canada, an action the president has advocated as a way to bring cheaper prescription drugs to Americans, but the pharmaceutical industry was quick to resist the move.

Pfizer to spinoff, merge off-patent drugs unit with Mylan

30 Jul 2019

Pfizer Inc has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV , a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar. | Video

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

25 Jul 2019

NEW YORK Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

UPDATE 2-Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

25 Jul 2019

NEW YORK, July 25 Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Exclusive: White House preparing order that would cut drug prices for Medicare: sources

25 Jul 2019

NEW YORK U.S. President Donald Trump is considering a sweeping executive order that would cut prices on virtually all branded prescription drugs sold to Medicare and other government programs, according to two industry sources who had discussions with the White House.

Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

25 Jul 2019

NEW YORK, July 25 Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

U.S. senators announce bipartisan proposal to lower drug prices

24 Jul 2019

WASHINGTON/NEW YORK The top Republican and Democrat on the U.S. Senate Finance Committee announced a proposal to lower prescription drug prices on Tuesday that could save $100 billion in costs to government healthcare programs, and said the committee would vote on the legislation on Thursday.

World News